<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01829919</url>
  </required_header>
  <id_info>
    <org_study_id>N30-005</org_study_id>
    <nct_id>NCT01829919</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single &amp; Repeat Oral Administration in Healthy Postmenopausal Women</brief_title>
  <acronym>N30-005</acronym>
  <official_title>Evaluation of Pharmacokinetics of Paroxetine Following Single and Repeat Oral Administration of Mesafem (7.5 mg Paroxetine Mesylate) Capsules in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noven Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noven Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and
      elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate)
      Capsules 7.5 mg when given as a single dose and multiple doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is for research only and is not designed to treat a medical condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (Hour*ng/mL) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (ng/mL) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Kel (Hour^-1) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean t1/2 Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median t1/2 Single Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (Hour*ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</measure>
    <time_frame>Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</measure>
    <time_frame>Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</measure>
    <time_frame>Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (Hour) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</measure>
    <time_frame>Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Index Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg at Day 19</measure>
    <time_frame>Day 19</time_frame>
    <description>Accumulation Index is the ratio of AUC 0-24 after multiple doses versus a single dose. It is the increase in drug plasma concentration after multiple dosing until a steady state is reached. In this case the steady state Accumulation Index was calculated at Day 19. Accumulation Index is calculated at the end of the dosing period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluctuation Index (%) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</measure>
    <time_frame>Day 19</time_frame>
    <description>Fluctuation Index is (Cmax-Cmin)/Cavg,ss. It is peak trough fluctuation within one dosing interval at steady state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cavg,ss (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</measure>
    <time_frame>Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ct (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</measure>
    <time_frame>Day 19</time_frame>
    <description>C(t) is the measured plasma level &quot;Concentration&quot; of the drug at &quot;time = t&quot; expressed as nanograms per milliliter.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Postmenopausal Symptoms</condition>
  <arm_group>
    <arm_group_label>Brisdelle (paroxetine mesylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brisdelle (paroxetine mesylate) Capsules taken orally with 240 mL of water for 20 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brisdelle (paroxetine mesylate)</intervention_name>
    <description>All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
    <arm_group_label>Brisdelle (paroxetine mesylate)</arm_group_label>
    <other_name>Former Names: Mesafem capsules 7.5 mg or</other_name>
    <other_name>LDMP (Low-Dose Mesylate salt of Paroxetine)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects who are healthy postmenopausal, non-smoking women of any race and ≥40 years of age
        at screening.

        Exclusion Criteria:

        Subjects who have a recent history or presence of glaucoma, migraines, cardiovascular,
        hepato-biliary, renal, gastrointestinal, neurologic, psychiatric, dermatologic, pulmonary,
        cerebrovascular, endocrine, hematologic, thromboembolic, immunologic disease or any other
        disorder which requires physician care; subjects who have existing medical conditions which
        might interfere with absorption, distribution, metabolism, or excretion of study
        medication; history of self-injurious behavior; history of clinical diagnosis of
        depression; or treatment for depression; history of clinical diagnosis of border-line
        personality disorder; presence of any of the following psychiatric disorders within the
        timeframes specified: Major Depressive Disorder-Lifetime; Dysthymia-Past 2 Years; Bipolar
        Disorder-Lifetime; Panic Disorder-Lifetime; Agoraphobia-Past Month; Social Phobia-Past
        Month; Obsessive Compulsive Disorder-Past Month; Generalized Anxiety-Lifetime; Psychotic
        Disorders-Lifetime; Anorexia Nervosa-Past 10 Years; Bulimia-Past 10 Years;
        Suicidality/Suicide Ideation-Lifetime; Post Traumatic Stress Disorder-Lifetime.

        Subjects with a history of seizures; sitting blood pressure (BP) &lt; 90/50 or &gt; 150/90 mmHg;
        sitting heart rate (HR) &lt; 45 or &gt; 90 beats/min; clinical laboratory test results outside of
        the normal range for the laboratory conducting the test; positive urine pregnancy test at
        Screening or Day 0; subjects who have a history of sensitivity to active and/or inactive
        ingredients in Brisdelle (paroxetine mesylate) Capsules 7.5 mg; subjects who have a history
        of significant allergies; subjects who have a present or past history of narcotic
        addiction, drug abuse, or alcoholism; subjects who have smoked or used tobacco during the
        last 6 months; subjects who have donated one or more pints of blood within 30 days prior to
        treatment administration; subjects who have symptoms of any significant acute illnesses at
        the screening visit; subjects who used any investigational drug within 30 days prior to
        treatment administration; subjects who took any substances known to be Cytochrome P450 2D6
        (CYP2D6) inhibitors within 14 days of study start and throughout the entire study; subjects
        who used any prescription medications within 14 days of the screening visit; subjects who
        used St John's Wort within 14 days of the screening visit; subjects who used any over the
        counter preparations including herbal or nutritional supplements and multivitamins within
        10 days prior to receiving the first study treatment; subjects who have consumed foods or
        beverages containing caffeine/xanthine or alcohol; subjects who have a positive screen for
        hepatitis B surface antigen (HBsAg) or hepatitis C antibody; subjects who have a positive
        screen for the Human Immunodeficiency Virus (HIV) antibody; subjects who have a positive
        urine drug screen; subjects who have any clinically significant illness within 90 days
        prior to receiving the first dose of study medication.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Al-Ibrahim, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>SNBL Clinical Pharmacology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.noven.com</url>
    <description>Sponsor</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2013</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2013</study_first_posted>
  <results_first_submitted>July 16, 2013</results_first_submitted>
  <results_first_submitted_qc>January 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2014</results_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menopause</keyword>
  <keyword>Hot flashes</keyword>
  <keyword>Vasomotor symptoms</keyword>
  <keyword>Climacteric symptoms</keyword>
  <keyword>perimenopause</keyword>
  <keyword>Mesafem</keyword>
  <keyword>Brisdelle</keyword>
  <keyword>Low-Dose Mesylate salt of Paroxetine (LDMP)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
          <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>24</population>
      <group_list>
        <group group_id="B1">
          <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
          <description>Brisdelle (paroxetine mesylate) Capsules
All subjects will receive Brisdelle (paroxetine mesylate) capsules, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC (Hour*ng/mL) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg</title>
        <time_frame>Day 1</time_frame>
        <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
            <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (Hour*ng/mL) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg</title>
          <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
          <units>Hour*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-last (Hour x ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.95" spread="166.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-inf (Hour x ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.80" spread="189.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-24 (Hour x ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.90" spread="51.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (ng/mL) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg</title>
        <time_frame>Day 1</time_frame>
        <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
            <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (ng/mL) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg</title>
          <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Kel (Hour^-1) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg</title>
        <time_frame>Day 1</time_frame>
        <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
            <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Kel (Hour^-1) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg</title>
          <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
          <units>Hour^(-1)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean t1/2 Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg</title>
        <time_frame>Day 1</time_frame>
        <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
            <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean t1/2 Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg</title>
          <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.30" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median t1/2 Single Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
        <time_frame>Day 1</time_frame>
        <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
            <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median t1/2 Single Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
          <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="1.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (Hour*ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
        <time_frame>Day 19</time_frame>
        <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
            <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (Hour*ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
          <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
          <units>Hour*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-last (Hour x ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237.34" spread="222.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-24 (Hour x ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237.28" spread="222.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
        <time_frame>Day 19</time_frame>
        <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
            <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
          <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.10" spread="11.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmin (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
        <time_frame>Day 19</time_frame>
        <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
            <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
          <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.67" spread="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax (Hour) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
        <time_frame>Day 19</time_frame>
        <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
            <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (Hour) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
          <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="3.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Index Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg at Day 19</title>
        <description>Accumulation Index is the ratio of AUC 0-24 after multiple doses versus a single dose. It is the increase in drug plasma concentration after multiple dosing until a steady state is reached. In this case the steady state Accumulation Index was calculated at Day 19. Accumulation Index is calculated at the end of the dosing period.</description>
        <time_frame>Day 19</time_frame>
        <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
            <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Index Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg at Day 19</title>
          <description>Accumulation Index is the ratio of AUC 0-24 after multiple doses versus a single dose. It is the increase in drug plasma concentration after multiple dosing until a steady state is reached. In this case the steady state Accumulation Index was calculated at Day 19. Accumulation Index is calculated at the end of the dosing period.</description>
          <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.71" lower_limit="0.12" upper_limit="23.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fluctuation Index (%) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
        <description>Fluctuation Index is (Cmax-Cmin)/Cavg,ss. It is peak trough fluctuation within one dosing interval at steady state.</description>
        <time_frame>Day 19</time_frame>
        <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
            <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluctuation Index (%) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
          <description>Fluctuation Index is (Cmax-Cmin)/Cavg,ss. It is peak trough fluctuation within one dosing interval at steady state.</description>
          <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
          <units>Percentage of steady state concentration</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.76" lower_limit="35.57" upper_limit="153.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cavg,ss (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
        <time_frame>Day 19</time_frame>
        <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
            <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cavg,ss (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
          <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.89" spread="9.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ct (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
        <description>C(t) is the measured plasma level &quot;Concentration&quot; of the drug at &quot;time = t&quot; expressed as nanograms per milliliter.</description>
        <time_frame>Day 19</time_frame>
        <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
            <description>Brisdelle (paroxetine mesylate) Capsules 7.5 mg
All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ct (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg</title>
          <description>C(t) is the measured plasma level &quot;Concentration&quot; of the drug at &quot;time = t&quot; expressed as nanograms per milliliter.</description>
          <population>Safety and evaluable pharmacokinetic populations = 24 randomized subjects.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cτ18 (ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.53" spread="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cτ19 (ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.35" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cτ20 (ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.79" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Brisdelle (Paroxetine Mesylate) Capsules</title>
          <description>Brisdelle (paroxetine mesylate) Capsules
All subjects will receive Brisdelle (paroxetine mesylate) capsules, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sailaja Bhaskar, Executive Director, Clinical Research</name_or_title>
      <organization>Noven Therapeutics, LLC</organization>
      <phone>(212) 287-0798</phone>
      <email>sbhaskar@noven.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

